Discover and read the best of Twitter Threads about #ASCO2019
Most recents (4)
One of my labors of love. Appropriately online on Valentine’s Day! ❤️ Perioperative gFOLFIRINOX for #GEA with premptive iri dose reduction of hi risk UGT1A1 genotypes. ja.ma/2vCgd7T @UCCancerCenter @kturaga @SteveMaronMD with nice commentary @JoeChaoMD & @KlempnerSam.
The presentation of this poster at #ASCO2019, you can imagine, didn’t have any investors hovering around 😏.
🚨Tweetorial: NTRK 101 🚨Given the data discussed at @asco #ASCO2019 & @sno #SNO2019 on #NTRK fusions in primary brain tumors & brain mets, I thought we could review the background of these fusions, how to find them, and then look at potential options for tx. #btsm
<Disclaimer: I’m a speaker for Bayer (larotrectinib) and a subI for the STARTRK trial using entrectinib. I also have ongoing research work w @carisls > I’m keeping this as bias-free as possible though. Ok, next...
Surprise surprise. The group that benefits from 1L pembro is largely driven by MSI-high tumors. This should have been included in the original #ASCO2019 presentation. 😡 #KN062 #ESMO2019
THREAD: (1/10) Our work in JCO PO looked at NGS data from patients with met lung adeno. Some goals: (1) explore notion of molecular staging (within stage IV) using somatic mut & (2) see what drives poorer outcomes under current standard of care ascopubs.org/doi/full/10.12… #MSKIMPACT 
(2/10) We knew some single-gene mutations were good (e.g. EGFR, ALK) or bad predictive/prognostic determinants. OncoCast helped broadly explore effect of genes & gene combinations using an ensemble statistical learning strategy
(3/10)Some genes like STK11 and KEAP1 came out as neg survival factors on most runs of model. EGFR came out as positive. Interesting to look at the size of effect on survival (KRAS came out a lot, but wasn’t as strong a negative effect as STK11 or KEAP1)
